STOCK TITAN

4D Molecular Therapeutics: BVF reports ~9.99% stake

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

4D Molecular Therapeutics, Inc. (FDMT) ownership amendment reports that affiliated funds and entities may be deemed to beneficially own its common stock. As of September 30, 2026, BVF Partners L.P., BVF Inc. and Mark N. Lampert each may be deemed to beneficially own 5,811,860 shares, or approximately 9.99% of the class.

The reporting persons and a Partners managed account held Pre-Funded Warrants exercisable for 7,544,945 shares at $0.0001 per share. The warrants' 9.99% blocker limited their aggregate exercise to 2,932,571 shares. The statement describes shared voting and dispositive power and says the reporting persons do not admit to beneficial ownership of shares attributed to another reporting person.

Beneficially owned shares 5,811,860 shares Each of BVF Partners L.P., BVF Inc. and Mark N. Lampert may be deemed to beneficially own this amount as of September 30, 2026.
Reported ownership percentage Approximately 9.99% Each of BVF Partners L.P., BVF Inc. and Mark N. Lampert may be deemed to own this percentage of the class as of September 30, 2026.
Shares underlying Pre-Funded Warrants 7,544,945 shares Warrants held by the reporting persons and a Partners managed account as of September 30, 2026.
Aggregate exercise limit 2,932,571 shares Limit under the Pre-Funded Warrants Blocker as of September 30, 2026.
Exercise price $0.0001 per share Pre-Funded Warrants.
Shares outstanding 55,244,211 shares Issuer shares outstanding as of August 10, 2026; used in the statement's ownership-percentage denominator.
Pre-Funded Warrants financial
"held Pre-Funded Warrants exercisable for an aggregate of 7,544,945 shares"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
Pre-Funded Warrants Blocker regulatory
"the Pre-Funded Warrants Blocker limits the aggregate exercise"
beneficial ownership regulatory
"may be deemed to beneficially own the 5,811,860 Shares"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
shared voting power regulatory
"Shared Voting Power 5,811,860.00"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
Section 13(d) regulatory
"aggregated for the purposes of Section 13(d) of the Exchange Act"
A Section 13(d) filing is a public disclosure required under U.S. securities law when a person or group acquires more than 5% of a company’s registered equity and may influence control. The filer must report who owns the shares, how they were acquired, and any plans or intentions for the company, so the market and other shareholders can see if a large buyer is attempting a takeover or other strategic move. Think of it like a formal announcement that someone has crossed a threshold and is showing their hand.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many FDMT shares did the reporting persons beneficially own?

BVF Partners L.P., BVF Inc. and Mark N. Lampert each may be deemed to beneficially own 5,811,860 shares, approximately 9.99% of the class. The statement says the reporting persons do not admit to beneficial ownership of shares attributed to another reporting person.

How many FDMT shares can be exercised under the reported Pre-Funded Warrants?

The 9.99% blocker limited aggregate exercise by the reporting persons and a Partners managed account to 2,932,571 shares as of September 30, 2026. The warrants were exercisable at $0.0001 per share and covered 7,544,945 shares in total.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





35104E100

(CUSIP Number)
09/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



BIOTECHNOLOGY VALUE FUND L P
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
BVF I GP LLC
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
BIOTECHNOLOGY VALUE FUND II LP
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
BVF II GP LLC
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
Biotechnology Value Trading Fund OS LP
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
BVF Partners OS Ltd.
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
BVF GP HOLDINGS LLC
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
BVF PARTNERS L P/IL
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
BVF INC/IL
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
LAMPERT MARK N
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert
Date:11/16/2026

Keep reading